01 December 2007
Therapeutic drug monitoring of immunosuppressive drugs – future perspectives
P. WallemacqAnn Transplant 2008; 13(1): 29-29 :: ID: 880183
Abstract
The dramatic improvement recorded during this last decade in the field of transplantation is mainly due both to the appearance of new immunosuppressive drugs (IS)/drug combinations and to a better understanding of the tenuous equilibrium between over- and under- immunosuppression. Current trends in drug association result in a progressive lowering of the IS charge and consequently in a reduction of their blood concentrations. There is no doubt that therapeutic drug monitoring (TDM) played an important role in this progress, because these are critical dose drugs: concentrations related side effects, inter-patient pharmacokinetics variability (bioavailability, metabolism, drug interactions, genetic polymorphism, ...). Analytical methods used to monitor these drugs also experienced some significant evolution with the use of LC-MSMS in clinical practice and with a constant progress in the immunoassays performances (sensitivity, specificity, reproducibility, automation). The area under the time-concentration curve (AUC) is generally considered as the best drug exposure marker, but is not appropriate in clinical practice. Single time points (mainly C0) IS concentrations remain therefore the most frequently used marker. Blood concentrations monitoring provides some helpful information to prevent side effects, drug interactions or non-compliance. Recent studies, however, suggest that the relationship between blood levels and incidence of organ rejection is not clearly established. Optimal treatment management needs therefore some additional approaches. Four personalized approaches are currently under investigation: 1. Optimization of the prediction of IS AUC with population pharmacokinetics, limited sampling strategy or Bayesian estimates, 2. Identification of genetic polymorphisms of metabolism enzymes or transport proteins (e.g. CYP3A5, P-gp, MRP2, etc.) to reach target drug concentration earlier, 3. Determination of IS drug concentration at the site of action (e.g. within target lymphocytes), and finally 4. Identification of pharmacodynamic biomarkers (e.g. intracellular IL2 in CD8+ T-cells, etc) able to better predict IS drug efficacy (and toxicity). This last approach is of particular interest and is expected to significantly progress during the coming years.
Keywords: Transplantation, immunosuppressive drugs, theory of mind
SARS-CoV-2/COVID-19
17 June 2022 : Case report
Extrapulmonary Manifestations of SARS-CoV-2: A Report of 3 Cases and a Literature ReviewAnn Transplant In Press; DOI: 10.12659/AOT.935874
12 April 2022 : Letter/Correspondence
Pancreas Allograft Thrombosis as a Post-COVID-19 Complication in a Diabetic Patient After Pancreas Transpla...Ann Transplant 2022; 27:e935863
12 November 2021 : Original article
Coronavirus Disease 2019 (COVID-19) in Solid Organ Transplant Recipients: A Case-Control StudyAnn Transplant 2021; 26:e933152
26 October 2021 : Original article
Safety of Antithymocyte Globulin Use in Kidney Graft Recipients During the COVID-19 PandemicAnn Transplant 2021; 26:e933001
In Press
23 Jun 2022 : Original article
Evaluation of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program in Comparison to S...Ann Transplant In Press; DOI: 10.12659/AOT.936514
21 Jun 2022 : Case report
Extrapulmonary Manifestations of SARS-CoV-2: A Report of 3 Cases and a Literature ReviewAnn Transplant In Press; DOI: 10.12659/AOT.935874
20 Jun 2022 : Original article
The Association Between Tacrolimus Levels and Hyperkalemia in Allograft Recipients Who Underwent Heart or L...Ann Transplant In Press; DOI: 10.12659/AOT.935607
15 Jun 2022 : Original article
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.936276
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860